Cargando…
Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
INTRODUCTION: The objective of this study was to evaluate the cost-effectiveness of initiating treatment with tofacitinib and subsequently incorporating it into a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) treatment sequence and to compare the cost-effectiveness of this s...
Autores principales: | Ha, So-Young, Shim, Yoon-Bo, Lee, Min-Young, Koo, Bon-San, Kim, Jae-Hoon, Jeon, Ja-Young, Yoo, Hyun-Jeong, Kim, Young-Joo, Shin, Ju-Young, Park, Mi-Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991041/ https://www.ncbi.nlm.nih.gov/pubmed/33496958 http://dx.doi.org/10.1007/s40744-021-00278-z |
Ejemplares similares
-
Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab
por: Kim, Seong-Kyu, et al.
Publicado: (2023) -
Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
por: Kim, Joon Wan, et al.
Publicado: (2013) -
Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
por: Koo, Bon San, et al.
Publicado: (2022) -
Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
por: Kim, Hyeongyeong, et al.
Publicado: (2021) -
Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats
por: Gwak, Eun Hye, et al.
Publicado: (2020)